Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ia trial to evaluate the safety, tolerability and pharmacokinetic properties of KAND-567 in Healthy Subjects.

Trial Profile

A phase Ia trial to evaluate the safety, tolerability and pharmacokinetic properties of KAND-567 in Healthy Subjects.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs KAND-567 (Primary)
  • Indications Autoimmune disorders; Cancer; Cancer pain
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Feb 2018 Results presented in a Kancera media release.
    • 20 Feb 2018 Results presented in a Kancera media release.
    • 04 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top